Investment Management of Virginia LLC lowered its position in shares of Becton Dickinson (NYSE:BDX) by 2.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,329 shares of the medical instruments supplier’s stock after selling 349 shares during the period. Investment Management of Virginia LLC’s holdings in Becton Dickinson were worth $3,322,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Amica Retiree Medical Trust increased its position in shares of Becton Dickinson by 325.0% during the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock valued at $109,000 after acquiring an additional 390 shares in the last quarter. Almanack Investment Partners LLC. bought a new stake in shares of Becton Dickinson during the fourth quarter valued at approximately $109,000. FTB Advisors Inc. increased its position in shares of Becton Dickinson by 114.2% during the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 290 shares in the last quarter. Advisors Preferred LLC bought a new stake in shares of Becton Dickinson during the fourth quarter valued at approximately $126,000. Finally, Truewealth LLC bought a new stake in Becton Dickinson in the 4th quarter worth approximately $133,000. 84.45% of the stock is owned by institutional investors.
Shares of BDX stock opened at $223.73 on Monday. Becton Dickinson has a 1 year low of $185.33 and a 1 year high of $248.39. The company has a quick ratio of 1.12, a current ratio of 1.70 and a debt-to-equity ratio of 1.07. The firm has a market cap of $59.78 billion, a PE ratio of 23.60, a price-to-earnings-growth ratio of 1.56 and a beta of 1.15.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 29th. Investors of record on Friday, June 8th will be paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date of this dividend is Thursday, June 7th. Becton Dickinson’s dividend payout ratio (DPR) is 31.65%.
In related news, EVP Nabil Shabshab sold 10,209 shares of Becton Dickinson stock in a transaction on Friday, May 11th. The shares were sold at an average price of $226.10, for a total transaction of $2,308,254.90. Following the transaction, the executive vice president now owns 12,476 shares in the company, valued at approximately $2,820,823.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Alexandre Conroy sold 20,128 shares of Becton Dickinson stock in a transaction on Monday, May 21st. The shares were sold at an average price of $228.74, for a total transaction of $4,604,078.72. Following the transaction, the insider now owns 35,583 shares in the company, valued at approximately $8,139,255.42. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 37,560 shares of company stock worth $8,547,036. 1.00% of the stock is owned by corporate insiders.
A number of research firms have commented on BDX. ValuEngine raised shares of Becton Dickinson from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $260.00 target price (up previously from $223.00) on shares of Becton Dickinson in a research report on Tuesday, February 6th. Morgan Stanley lifted their target price on shares of Becton Dickinson from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. BMO Capital Markets began coverage on shares of Becton Dickinson in a research report on Monday, March 5th. They issued a “market perform” rating and a $249.00 target price for the company. Finally, Zacks Investment Research downgraded shares of Becton Dickinson from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $241.19.
Becton Dickinson Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson (NYSE:BDX).
Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.